منابع تحقیق درمورد of، and، همبستگی

GA-PLS
Observed
Molecule
-0.478
-2.002
-2.480
21
0.272
-2.272
-2.000
1
-0.409
-2.191
-2.600
22
0.320
-2.650
-2.330
2
-0.417
-2.063
-2.480
23
-0.366
-3.144
-3.510
3
0.122
-1.902
-1.780
24
-0.030
-3.420
-3.450
4
-1.155
-2.025
-3.180
25
0.416
-2.416
-2.000
5
0.410
-2.260
-1.850
26
0.687
-2.987
-2.300
6
-0.471
-1.829
-2.300
27
0.828
-1.908
-1.080
7
-0.660
-2.190
-2.850
28
-0.847
-2.453
-3.300
8
0.564
-1.824
-1.260
39
-0.835
-2.645
-3.480
9
0.070
-1.770
-1.700
30
0.593
-2.703
-2.110
10
0.343
-1.193
-0.850
31
-0.294
-3.406
-3.700
11
0.097
-1.577
-1.480
32
0.845
-3.205
-2.360
12
0.474
-1.674
-1.200
33
-0.755
-2.425
-3.180
13
0.398
-1.388
-0.990
34
-0.166
-2.564
-2.730
14
1.060
-1.910
-0.850
35
-0.140
-2.090
-2.230
15
0.617
-1.617
-1.000
36
-0.303
-2.297
-2.600
16
0.246
-1.986
-1.740
37
0.211
-2.811
-2.600
17
1.422
-2.322
-0.900
38
0.193
-3.393
-3.200
18
0.165
-2.275
-2.110
39
-1.339
-2.021
-3.360
19
-0.426
-1.724
-2.150
40
-1.262
-1.968
-3.230
20
جدول 3-115. مقادیر عددی مشاهدات، پیش بینی با روشGA-PLS ، ?? و انحراف برای همبستگی با هدف 4/0 برای لایه 10
??
Predicted GA-PLS
Observed
Molecule
??
Predicted GA-PLS
Observed
Molecule
-0.118
-2.362
-2.480
21
0.327
-2.327
-2.000
1
-0.550
-2.050
-2.600
22
0.529
-2.859
-2.330
2
-0.432
-2.048
-2.480
23
-0.291
-3.219
-3.510
3
-0.213
-1.567
-1.780
24
-0.837
-2.613
-3.450
4
-0.576
-2.604
-3.180
25
0.286
-2.286
-2.000
5
0.679
-2.529
-1.850
26
0.563
-2.863
-2.300
6
0.166
-2.466
-2.300
27
0.820
-1.900
-1.080
7
-0.294
-2.556
-2.850
28
-1.105
-2.195
-3.300
8
0.106
-1.366
-1.260
39
-1.178
-2.302
-3.480
9
0.325
-2.025
-1.700
30
0.756
-2.866
-2.110
10
0.922
-1.772
-0.850
31
-0.535
-3.165
-3.700
11
0.387
-1.867
-1.480
32
0.354
-2.714
-2.360
12
0.084
-1.284
-1.200
33
-0.499
-2.681
-3.180
13
0.674
-1.664
-0.990
34
-0.521
-2.209
-2.730
14
1.670
-2.520
-0.850
35
-0.417
-1.813
-2.230
15
0.139
-1.139
-1.000
36
-0.346
-2.254
-2.600
16
0.496
-2.236
-1.740
37
0.358
-2.958
-2.600
17
0.618
-1.518
-0.900
38
0.417
-3.617
-3.200
18
-0.364
-1.746
-2.110
39
-1.226
-2.134
-3.360
19
-0.336
-1.814
-2.150
40
-0.837
-2.393
-3.230
20
جدول3-116. مقادیر عددی مشاهدات، پیش بینی با روشGA-PLS ، ?? و انحراف برای همبستگی با هدف 4/0 برای لایه 11
??
Predicted GA-PLS
Observed
Molecule
??
Predicted GA-PLS
Observed
Molecule
-0.134
-2.346
-2.480
21
0.328
-2.328
-2.000
1
-0.526
-2.074
-2.600
22
0.569
-2.899
-2.330
2
-0.391
-2.089
-2.480
23
-0.293
-3.217
-3.510
3
-0.199
-1.581
-1.780
24
-0.701
-2.749
-3.450
4
-0.609
-2.571
-3.180
25
0.281
-2.281
-2.000
5
0.660
-2.510
-1.850
26
0.585
-2.885
-2.300
6
0.191
-2.491
-2.300
27
0.805
-1.885
-1.080
7
-0.299
-2.551
-2.850
28
-1.112
-2.188
-3.300
8
0.074
-1.334
-1.260
39
-1.162
-2.318
-3.480
9
0.300
-2.000
-1.700
30
0.798
-2.908
-2.110
10
0.879
-1.729
-0.850
31
-0.425
-3.275
-3.700
11
0.269
-1.749
-1.480
32
0.390
-2.750
-2.360
12
0.057
-1.257
-1.200
33
-0.496
-2.684
-3.180
13
0.592
-1.582
-0.990
34
-0.499
-2.231
-2.730
14
1.577
-2.427
-0.850
35
-0.397
-1.833
-2.230
15
0.144
-1.144
-1.000
36
-0.347
-2.253
-2.600
16
0.401
-2.141
-1.740
37
0.428
-3.028
-2.600
17
0.624
-1.524
-0.900
38
0.421
-3.621
-3.200
18
-0.381
-1.729
-2.110
39
-1.193
-2.167
-3.360
19
-0.412
-1.738
-2.150
40
-0.797
-2.433
-3.230
20
جدول 3-117. مقادیر عددی مشاهدات، پیش بینی با روش GA-PLS، ?? و انحراف برای همبستگی با هدف 4/0 برای لایه 12
??
Predicted GA-PLS
Observed
Molecule
??
Predicted GA-PLS
Observed
Molecule
-0.274
-2.206
-2.480
21
0.209
-2.209
-2.000
1
-0.422
-2.178
-2.600
22
0.546
-2.876
-2.330
2
-0.568
-1.912
-2.480
23
-0.338
-3.172
-3.510
3
-0.272
-1.508
-1.780
24
-0.521
-2.929
-3.450
4
-0.572
-2.608
-3.180
25
0.259
-2.259
-2.000
5
0.663
-2.513
-1.850
26
0.453
-2.753
-2.300
6
0.305
-2.605
-2.300
27
0.944
-2.024
-1.080
7
-0.204
-2.646
-2.850
28
-1.135
-2.165
-3.300
8
0.266
-1.526
-1.260
39
-1.337
-2.143
-3.480
9
0.537
-2.237
-1.700
30
0.772
-2.882
-2.110
10
0.606
-1.456
-0.850
31
-0.345
-3.355
-3.700
11
0.120
-1.600
-1.480
32
0.575
-2.935
-2.360
12
0.102
-1.302
-1.200
33
-0.669
-2.511
-3.180
13
0.588
-1.578
-0.990
34
-0.541
-2.189
-2.730
14
1.430
-2.280
-0.850
35
-0.744
-1.486
-2.230
15
0.401
-1.401
-1.000
36
-0.400
-2.200
-2.600
16
0.356
-2.096
-1.740
37
0.377
-2.977
-2.600
17
0.772
-1.672
-0.900
38
0.368
-3.568
-3.200
18
-0.174
-1.936
-2.110
39
-1.117
-2.243
-3.360
19
-0.209
-1.941
-2.150
40
-0.807
-2.423
-3.230
20
جدول3- 118. توصیفگرهای انتخاب شده از روش GA-ANN برای همبستگی با هدف 3/0
Meaning
Descriptor group
Descriptor symbol
Moran autocorrelation – lag 4 / weighted by atomic van der Waals volumes
2D autocorrelations
MATS4v
mean atomic polarizability (scaled on Carbon atom)
Constitutional descriptors
Mp
average valence connectivity index chi-4
Connectivity indices
X4Av
Radial Distribution Function – 9.5 / weighted by atomic polarizabilities
RDF descriptors
RDF095p
frequency of C – S at topological distance 10
2D frequency fingerprints
F10[C-S]
جدول3-119. توصیفگرهای انتخاب شده از روش GA-ANN برای همبستگی با هدف 4/0
Meaning
Descriptor group
Descriptor symbol
Radial Distribution Function – 13.5 / unweighted
RDF descriptors
RDF135u
H autocorrelation of lag 7 / unweighted
GETAWAY descriptors
H7u
H attached to C0(sp3) no X attached to next C
Atom-centred fragments
H-046
information content index (neighborhood symmetry of 2-order)
Information indices
IC2
Geary autocorrelation – lag 2 / weighted by atomic masses
2D autocorrelations
GATS2m
Radial Distribution Function – 8.5 / weighted by atomic polarizabilities
RDF descriptors
RDF085p
فصل چهارم
پیوست 2
نمودار ها
نمودار4-1. نمودار بدست آمده از روش GA-ANN برای همبستگی با هدف 3/0
نمودار4-2. نمودار بدست آمده از روش GA-ANN برای همبستگی با هدف 4/0
نمودار4- 3 بدست آمده از روش stepwiseMLR با همبستگی3/0
نمودار 4-4 بدست آمده ازروش stepwiseMLRبا همبستگی 3/0
نمودار4- 5 بدست آمده ازروش stepwiseMLR با همبستگی 4/0
نمودار4- 6. بدست آمده ازروش stepwiseMLR با همبستگی 4/0
نمودار4- 7-نمودار GA لایه12 همبستگی 3/0
نمودار4- 8-نمودار GA لایه 8 همبستگی 3/0
نمودار4-9-نمودار GA لایه 7 همبستگی 4/0
.
نمودار4-10- نمودار GA لایه12 همبستگی4/0
منابع
[1] D. C. Young. A Guide for Computational and Medicinal Chemists.Hoboken by John Wiley & Sons.2009. p.1-5
[2] Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.2004(27) s5-s10
[3]K.Polonsky.The Past 200 Years in Diabetes. T h e new engl and journa l o f medicine. 2012(367)1332-40
[4]J.Zajac,L.Poretsky.The main of Diabetes Mellitus.Springer Scienes +Business Media,LLC. 2010(387)09841-8
[5] A. Buchanan, L. Kjos, A. Xiang and R. Watanabe. What Is Gestational Diabetes.Journal Diabetes Care.2007(30)s105-s111
[6]S.Inzucchi.Diagnosis of Diabetes.T h e new engl and journa l o f medicine. 2012(367)542-50
[7]Standards of Medical Care in Diabetes. JournalDiabetes Care.2011(34)s11-s61
[8]S. Bolen, MD, L. Feldman, J. Vassy, L. Wilson, H.Chieh Yeh,S. Marinopoulos, C. Wiley, E. Selvin, R. Wilson, E B.Bass,and F L. Brancati. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus.Annals of Internal Medicine.2007(147)386-400
[9]H.Laube. Acarbose. Journal Clin Druginvest.2002(3)141-156
[10] M.Stumvoll, N.Nurjhan, G.Perriello, G.dailey and J.Gericll. Metabolic Effects of Metformin in non -insulin Dependent Diabetes Mellitus.The New England Journal of Medicine.1995(333)550-554
[11] V. A. Fonseca. Pioglitazone. Pioglitazone . JournalDrugs.2000(60)344-345
[12] C. R. Culy, B. Jarvis. Repaglinide.JournalDrugs.2001(61)1625-1660
[13] H. D. Breidah, G. C. Enni, F. I. R. Martin, J. R. Stawell and P. Taft. Insulin and Oral Hypoglycaemic Agents. JournalDrugs.1972(3)79-107
[14] L.Goldman, A.I.Shafer.Goldman?s Cecil Medicine.Cecil Textbook of medicine.2011(24)e236-5
[15] M. Weck,T Slesaczeck, H. Paetzold, D.Muench, T. Nanning, G. von Gagern, A. Brechow, U. Dietrich, M. Holfert, S. Bornstein, A. Barthel, A. Thomas C. Koehler and M. Hanefeld. Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates. Journal Cardiovascular Diabetology.2013(12)1-9
[16] D.G. Armstrong , L.A. Lavery , L.B. Harkless .Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemiato risk of amputation. Journal Diabetes Care.1998(21)5855-859
[17] S .Nani , S .Hassoune , N .Chinab , Z .Boumdi and A .Maaroufi . Survey of general practioners in the management of diabetes in primary health facilities of Casablanca city, Morocco: opportunities and constraints. Journal Tunisie Mediacale.2013(91)410-4
[18] R. Thiyagarajan, SK. Subramanian, N. Sampath , T. Madanmohan , P. Pal , Z. Bobby , S .Paneerselvam and AK .Das .Association betweencardiac autonomic function, oxidative stress and inflammatory response in impaired fasting glucose subjects: cross-sectional study. journal.pone.2012(7)e41889
[19] O. Salahuddin, M. Azhar, Aqsa Imtiaz, and M.

دیدگاهتان را بنویسید